News and commentary from the psychiatry world
— News and commentary from the psychiatry world
May 20, 2026
• 2 min read
A single infusion of the interleukin (IL)-6 inhibitor tocilizumab (Actemra) showed greater improvements in depression severity, somatic symptoms, fatigue, and anxiety in patients with difficult-to-treat depression and low-grade inflammation compared with placebo in a proof-of-concept trial. (JAMA Psychiatry)
A 3-minute video game-like task was able to monitor depression severity. (PNAS)
Anti-inflammatory drug could help millions of Brits who suffer from depression
Immunotherapy could be used to treat depression, early trial suggests
Depression treatment breakthrough as arthritis drug could ‘help millions’
‘Strikingly better’: Co-antibody combination tops golimumab, guselkumab in refractory IBD
Problem-solving intervention improves psychosocial symptoms in young adults with cancer
EU and US advisers split over AstraZeneca breast cancer drug
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
AI Psychosis in 2026 — What the New Evidence Actually Shows
Asthma outcomes improve for diverse patients in real world with tezepelumab
Biologic initiation, adherence rates in asthma deemed low
Researchers investigated for the first time whether tocilizumab could improve symptoms of depression in people who have not…
UK scientists find tocilizumab, commonly used for rheumatoid arthritis, may help antidepressant-resistant patients
Study finds promising results for treatment of depression in people who haven’t responded to standard antidepressants
Semaglutide linked to lowering rates of anxiety and depression in new study
Study finds participants saw reduction in depressive symptoms as researchers welcome ‘promising’ results
Researchers find DMT – used in shamanic rituals – in tandem with psychotherapy has significant effect
